The American market for the identification and rapid treatment of pathogens linked to biodefense
Report Scope: This report examines the current and future market potential of the United States market for the rapid identification and treatment of biodefense-related pathogens. It offers a detailed analysis of the competitive environment, regulatory scenario, technological advancements, drivers and restraints, and identifies opportunities and growth trends in the market.
New York, October 25, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “The US market for the identification and rapid treatment of biodefense-related pathogens” – https://www.reportlinker.com/p03326180/?utm_source=GNW
The report also covers market projections to 2026.
For market estimates, data is provided for the following year 2019, 2020, 2021 and 2026. The year 2020 is the base year and is forecast until the year 2026.
The report includes:
– 79 tables
– An overview of the US market for the identification and rapid treatment of pathogens linked to biodefense
– Global market trend analyzes, with data from 2019-2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) to 2026
– Discussion on the main market dynamics (DRO), technological advances and the regulatory landscape in the context of rapid pathogens linked to biodefense
– Assessing and forecasting the market size of Biodefense Pathogen Detection Products in terms of monetary value, and corresponding market share analysis by type, test method, device type, technology, application, etc.
– Highlights of emerging technology trends, opportunities and gaps estimating current and future demand for infectious agents with information on detection, vaccines and treatment, ongoing R&D activities and clinical trials, etc.
– Review of infectious agents, including smallpox, anthrax, plague and tularemia, as well as coverage of potentially harmful chemical toxins that are used in biological warfare situations, including sarin gas, ricin and botulinum
– The impact of COVID-19 on bioinformatics research and new developments concern diagnostic tools related to biodefense
– Examination of issued patents for rapid identification of pathogens and new industry specific developments
– Overview of recent industry strategies and competitive landscape of major players operating in the global market along with their company share analysis
– Profile descriptions of the main industry players, including ANP Technologies, Biomerieux, Haztech, Menon Biosensors, Merck, Thermo Fisher Scientific and GlaxoSmithKline
Despite the 1975 Biological Weapons Commission renewal in 2009, the US State Department estimates that more than a dozen countries are developing biological weapons. The possibility that national or international terrorist groups may acquire or create biological weapons and use them against unprotected civilian or military targets is of great concern. The literal anthrax attacks in 2001, which resulted in the infection of 23 Americans and the death of five, increased Americans’ sense of vulnerability. Since 2001, the U.S. government has spent or allocated more than $ 60 billion on biological weapons research, which has included the development and distribution of air sensors, education
doctors on the symptoms of bioterrorist pathogens and the distribution of biodefense medical supplies to hospitals.
Biological substances that can be turned into weapons for civilian or military destruction are a problem associated with biodefense. The precise and rapid identification of these substances is at the heart of this report.
In addition, treatment methods such as vaccines and oral pharmaceuticals will be discussed.
Pathogens can be viruses, bacteria, fungi, protozoa, parasites, or manufactured toxins. They can cause disease in plants, animals and humans.
Pathogens harmful to animals and plants are not dealt with in this report unless they present an eminent danger, as brucellosis or plague has done, to humans through consumption. The infectious agents discussed in this report include smallpox, anthrax, plague and tularemia.
Another area of pathogen identification includes potentially harmful chemical toxins that are used in biological warfare situations, such as ricin and botulinum.
In the military and civilian arenas, the report covers products and strategies that identify pathogens introduced into air, water, and other means.
The process of rapidly identifying potentially dangerous pathogens falls into two categories: testing of samples (eg, immunoassay) and sensors (eg, airborne pathogens). Both identification methods are discussed in this report, and the potential markets for the products are projected through 2026.
The most commonly available detection tests are those aimed at detecting anthrax, smallpox and tularemia. Some tests can detect more than one pathogen simultaneously.
The most common combination tests include anthrax, smallpox, plague, tularemia, botulism, and staphylococcal enterotoxin B (SEB). Development of viral tests for pandemic influenza and COVID-19 is underway, but as with treatment, detection of viruses is more complicated than that of bacterial pathogens.
Read the full report: https://www.reportlinker.com/p03326180/?utm_source=GNW
On Report link
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001